IP Library Granted Patent US 10,456,458
Granted Patent B2
US 10,456,458 · App. 15/954,053 · Granted Oct 29, 2019

Immunogenic composition of killed leptospira bacteria

Inventors: Henricus Leo Bernardus Maria Klaasen (Wijchen, NL); Eric Onno Rijke (Boxmeer, NL)
Assignee: Intervet Inc.
A61K39/0225A61K9/08A61K47/02A61K47/183A61K2039/521
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,456,458
App. No.
15/954,053
Granted
Oct 29, 2019
Kind
B2
Abstract

The present invention pertains to a composition containing an immunogenic cell preparation of killed Leptospira bacteria in an ethylenediaminetetraacetic acid solution. The invention also pertains to a vaccine to protect an animal against an infection with leptospira bacteria, wherein the vaccine comprises this composition. Also, the invention pertains to the use of ethylenediaminetetraacetic acid to stabilise an immunogenic preparation of killed Leptospira bacteria in a liquid carrier, by dissolving the ethylenediaminetetraacetic acid in the carrier.

Claims (14)

1. A composition containing an immunogenic cell preparation of killed Leptospira bacteria in an ethylenediaminetetraacetic acid solution; wherein the solution comprises 5 to 50 mmols of ethylenediaminetetraacetic acid per liter; wherein the Leptospira bacteria are selected from the group consisting of Leptospira interrogans serogroup Canicola serovar Portland-Vere, Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni, and Leptospira kirschneri serogroup Grippotyphosa serovar Dadas.

2. The composition of claim 1 , wherein the solution comprises 20 mmols of ethylenediaminetetraacetic acid per liter.

3. The composition of claim 2 , wherein the solution contains dibasic sodium phosphate.

4. The composition of claim 1 , wherein the solution contains dibasic sodium phosphate.

5. The composition of claim 1 , wherein the Leptospira bacteria are Leptospira interrogans serogroup Canicola serovar Portland-Ver.

6. A vaccine to protect an animal against an infection with leptospira bacteria, wherein the vaccine comprises the composition of claim 5 .

7. A vaccine to protect an animal against an infection with leptospira bacteria, wherein the vaccine comprises a composition of claim 2 .

8. A vaccine to protect an animal against an infection with leptospira bacteria, wherein the vaccine comprises the composition of claim 4 .

9. A vaccine to protect an animal against an infection with leptospira bacteria, wherein the vaccine comprises the composition of claim 3 .

10. A vaccine to protect an animal against an infection with leptospira bacteria, wherein the vaccine comprises the composition of claim 1 .

11. A method of stabilizing an immunogenic preparation of killed Leptospira bacteria in a liquid carrier, comprising dissolving ethylenediamine-tetraacetic acid in the liquid carrier; wherein the solution comprises 5 to 50 mmols of ethylenediaminetetraacetic acid per liter; wherein the Leptospira bacteria are selected from the group consisting of Leptospira interrogans serogroup Canicola serovar Portland-Vere, Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni, and Leptospira kirschneri serogroup Grippotyphosa serovar Dadas.

12. The method of claim 11 wherein the preparation retains at least 25% of its antigenic mass during a 3 month storage at a temperature above 18° C.

13. The method of claim 11 wherein the preparation retains at least 25% of its antigenic mass during a 3 month storage at a temperature between 18° C. and 37° C.

14. The method of claim 11 wherein the preparation retains at least 25% of its antigenic mass during a 3 month storage at 37° C.

Assignments (1)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
Priority Claims (1)
EP 12180793 · Aug 17, 2012 · regional
Continuity (3)
Continuation 15288465 · Oct 7, 2016
Division 14420946
Related Publication 20180228900A1 · Aug 16, 2018